AKT1 and diffuse large B-cell lymphoma: Whereas PI3Kβ/δ inhibition resulted in an initial reduction of the activity of the AKT/mTOR/S6 axis in the majority of the DLBCLs, we observed a reactivation of the signaling pathway after 24 h in the AZD8186-resistant DLBCL models.